share_log

Standard BioTools Inc. (NASDAQ:LAB) Surges 6.7%; Individual Investors Who Own 35% Shares Profited Along With Institutions

Standard BioTools Inc. (NASDAQ:LAB) Surges 6.7%; Individual Investors Who Own 35% Shares Profited Along With Institutions

標準生物工具公司(納斯達克股票代碼:LAB)飆升6.7%;擁有35%股票的個人投資者與機構一起獲利
Simply Wall St ·  04/09 18:47

Key Insights

關鍵見解

  • The considerable ownership by individual investors in Standard BioTools indicates that they collectively have a greater say in management and business strategy
  • 51% of the business is held by the top 6 shareholders
  • Institutions own 30% of Standard BioTools
  • 個人投資者對Standard BioTools的大量所有權表明,他們在管理和業務戰略中集體擁有更大的發言權
  • 51% 的業務由前6名股東持有
  • 機構擁有標準生物工具30%的股份

To get a sense of who is truly in control of Standard BioTools Inc. (NASDAQ:LAB), it is important to understand the ownership structure of the business. We can see that individual investors own the lion's share in the company with 35% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

要了解誰真正控制了標準生物工具公司(納斯達克股票代碼:LAB),了解業務的所有權結構非常重要。我們可以看到,個人投資者擁有公司的大部分股份,所有權爲35%。也就是說,如果股票上漲,該集團將受益最大(如果股價下跌,則損失最大)。

While individual investors were the group that benefitted the most from last week's US$69m market cap gain, institutions too had a 30% share in those profits.

儘管個人投資者是上週6900萬美元市值增長中受益最大的群體,但機構在這些利潤中也佔有30%的份額。

In the chart below, we zoom in on the different ownership groups of Standard BioTools.

在下圖中,我們放大了標準BioTools的不同所有權組。

ownership-breakdown
NasdaqGS:LAB Ownership Breakdown April 9th 2024
NASDAQGS: 實驗室所有權明細 2024 年 4 月 9 日

What Does The Institutional Ownership Tell Us About Standard BioTools?

關於標準生物工具,機構所有權告訴我們什麼?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。

Standard BioTools already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Standard BioTools, (below). Of course, keep in mind that there are other factors to consider, too.

標準BioTools已經在股票登記處設立了機構。事實上,他們擁有該公司可觀的股份。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。如果兩個大型機構投資者試圖同時拋售股票,股價大幅下跌的情況並不少見。因此,值得查看標準BioTools過去的收益軌跡(見下文)。當然,請記住,還有其他因素需要考慮。

earnings-and-revenue-growth
NasdaqGS:LAB Earnings and Revenue Growth April 9th 2024
NASDAQGS: LAB 收益和收入增長 2024 年 4 月 9 日

It looks like hedge funds own 15% of Standard BioTools shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Casdin Capital, LLC is currently the largest shareholder, with 16% of shares outstanding. Viking Global Investors LP is the second largest shareholder owning 15% of common stock, and Nippon Life India Asset Management Limited holds about 10% of the company stock.

看來對沖基金擁有標準生物工具15%的股份。這很有趣,因爲對沖基金可以非常活躍和活躍。許多人正在尋找推動股價上漲的中期催化劑。Casdin Capital, LLC目前是最大股東,已發行股份的16%。Viking Global Investors LP是第二大股東,擁有15%的普通股,日本人壽印度資產管理有限公司持有該公司約10%的股份。

We did some more digging and found that 6 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我們做了進一步的挖掘,發現大股東中有6人約佔登記冊的51%,這意味着除了較大的股東外,還有一些較小的股東,從而在一定程度上平衡了彼此的利益。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種好做法。分析師對該股的報道很少,但報道不多。因此,它還有獲得更多報道的餘地。

Insider Ownership Of Standard BioTools

標準生物工具的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

Our data suggests that insiders own under 1% of Standard BioTools Inc. in their own names. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. Keep in mind that it's a big company, and the insiders own US$10m worth of shares. The absolute value might be more important than the proportional share. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.

我們的數據表明,內部人士以自己的名義擁有標準生物工具公司不到1%的股份。但是,我們確實注意到,內部人士有可能通過私營公司或其他公司結構獲得間接利益。請記住,這是一家大公司,內部人士擁有價值1000萬美元的股票。絕對值可能比比例份額更重要。看到至少有一部分內部所有權總是件好事,但可能值得檢查一下這些內部人士是否一直在出售。

General Public Ownership

一般公有制

With a 35% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Standard BioTools. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

擁有35%所有權的公衆(主要由個人投資者組成)對標準BioTools有一定程度的影響力。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。

Private Equity Ownership

私募股權所有權

With an ownership of 16%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

私募股權公司擁有16%的所有權,可以在制定以價值創造爲重點的公司戰略方面發揮作用。一些投資者可能會爲此感到鼓舞,因爲私募股權有時能夠鼓勵制定有助於市場看到公司價值的策略。或者,這些持有人可能會在投資上市後退出投資。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for Standard BioTools you should be aware of.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。一個很好的例子:我們發現了標準生物工具的兩個警告信號,你應該注意了。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

歸根結底,未來是最重要的。您可以訪問這份關於公司分析師預測的免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論